IL-23 stabilizes an effector Treg cell program in the tumor microenvironment

Tobias Wertheimer,Pascale Zwicky,Lukas Rindlisbacher, Colin Sparano,Marijne Vermeer,Bruno Marcel Silva de Melo,Claudia Haftmann, Tamina Rueckert,Aakriti Sethi, Stefanie Schaerli, Anna Huber,Florian Ingelfinger, Caroline Xu, Daehong Kim, Philipp Haene, Andre Fonseca da Silva,Andreas Muschaweckh, Nicolas Nunez,Sinduya Krishnarajah, Natalie Koehler,Robert Zeiser,Mohamed Oukka,Thomas Korn,Sonia Tugues,Burkhard Becher

NATURE IMMUNOLOGY(2024)

引用 0|浏览4
暂无评分
摘要
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23 fuels tumor growth is unclear. Here, we found tumor-associated macrophages to be the main source of IL-23 in mouse and human tumor microenvironments. Among IL-23-sensing cells, we identified a subset of tumor-infiltrating regulatory T (T-reg) cells that display a highly suppressive phenotype across mouse and human tumors. The use of three preclinical models of solid cancer in combination with genetic ablation of Il23r in T-reg cells revealed that they are responsible for the tumor-promoting effect of IL-23. Mechanistically, we found that IL-23 sensing represents a crucial signal driving the maintenance and stabilization of effector T-reg cells involving the transcription factor Foxp3. Our data support that targeting the IL-23/IL-23R axis in cancer may represent a means of eliciting antitumor immunity.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要